文献速递先天性心脏病外科瓣膜外科

欧洲去细胞同种肺动脉瓣置换研究:ESPOIR试验与注册初步结果

A European study on decellularized homografts for pulmonary valve replacement: initial results from the prospective ESPOIR Trial and ESPOIR Registry data†.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

这项前瞻性欧洲多中心研究评估去细胞肺动脉同种移植物(DPH)用于肺动脉瓣置换的安全性和有效性,并将DPH与牛颈静脉带瓣管道(BJV)和冷冻保存同种移植物(CH)进行匹配比较。结果显示DPH手术操作安全,中短期血流动力学良好,联合注册数据后DPH在免除移植物取出和结构性瓣膜衰败方面优于BJV和CH。

要点

  • DPH用于肺动脉瓣置换手术操作安全,无操作相关不良事件。
  • 随访2.2±0.6年,DPH平均峰值压差16.1±12.1 mmHg,反流程度良好。
  • 联合注册数据10年免除移植物取出率DPH优于CH和BJV。

核心结论

  • 前瞻性多中心ESPOIR试验初步结果显示DPH安全有效,联合注册数据后DPH结果优于BJV和CH。

研究设计与样本

  • 前瞻性欧洲多中心试验,2014年8月至2016年12月入组121例患者(59例女性),年龄21.3±14.4岁,DPH直径24.4±2.8 mm。
  • 将DPH与BJV和CH按患者年龄、心脏缺陷类型和既往手术进行匹配比较。
  • 注册部分纳入114例在试验前或试验外手术的DPH患者,年龄16.6±10.4岁,直径24.1±4.2 mm,随访5.1±3.0年。
  • 联合DPH队列共235例,匹配CH 235例和BJV 235例进行比较。

主要发现

  • 试验组无手术操作相关不良事件,早期死亡2例(30岁和59岁,多瓣膜术后心肌衰竭),无晚期死亡,死亡率1.7%。
  • 平均随访2.2±0.6年,平均峰值压差16.1±12.1 mmHg,反流平均0.25±0.48(0-3级)。
  • 1例因心包补片所致复发性瓣下狭窄再手术,1例对既往支架置入的左肺动脉行球囊扩张。
  • 联合DPH队列10年免除移植物取出率DPH 96.7±2.1%,CH 84.4±3.2%(P=0.029),BJV 82.7±3.2%(P=0.012)。
  • 10年结构性瓣膜衰败率DPH 61.4±6.6%,CH 39.9±4.4%(n.s.),BJV 47.5±4.5%(P=0.029)。

临床怎么用

  • DPH可作为肺动脉瓣置换的优选移植物,尤其适用于需避免抗凝或生物瓣衰败风险较高的患者。
  • 术中操作安全,无特殊技术限制,短期血流动力学良好。
  • 长期随访中DPH在免除移植物取出方面优于BJV和CH,支持其作为肺动脉瓣置换的可靠选择。

局限性

  • 试验随访时间较短(平均2.2±0.6年),长期耐久性需进一步验证。
  • 注册数据为回顾性收集,可能存在选择偏倚。
  • 匹配比较中CH组结构性瓣膜衰败差异未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Decellularized pulmonary homografts (DPH) have shown excellent results for pulmonary valve replacement. However, controlled multicentre studies are lacking to date. METHODS: Prospective European multicentre trial evaluating DPH for pulmonary valve replacement. Matched comparison of DPH to bovine jugular vein (BJV) conduits and cryopreserved homografts (CH) considering patient age, type of heart defect and previous procedures. RESULTS: In total, 121 patients (59 female) were prospectively enrolled (August 2014-December 2016), age 21.3 ± 14.4 years, DPH diameter 24.4 ± 2.8 mm. No adverse events occurred with respect to surgical handling; there were 2 early deaths (30 + 59 years) due to myocardial failure after multi-valve procedures and no late mortality (1.7% mortality). After a mean follow-up of 2.2 ± 0.6 years, the primary efficacy end points mean peak gradient (16.1 ± 12.1 mmHg) and regurgitation (mean 0.25 ± 0.48, grade 0-3) were excellent. One reoperation was required for recurrent subvalvular stenosis caused by a pericardial patch and 1 balloon dilatation was performed on a previously stented LPA. 100% follow-up for DPH patients operated before or outside the trial (n = 114) included in the ESPOIR Registry, age 16.6 ± 10.4 years, diameter 24.1 ± 4.2 mm, follow-up 5.1 ± 3.0 years. The combined DPH cohort, n = 235, comprising both Trial and Registry data showed significantly better freedom from explantation (DPH 96.7 ± 2.1%, CH 84.4 ± 3.2%, P = 0.029 and BJV 82.7 ± 3.2%, P = 0.012) and less structural valve degeneration at 10 years when matched to CH, n = 235 and BJV, n = 235 (DPH 61.4 ± 6.6%, CH 39.9 ± 4.4%, n.s., BJV 47.5 ± 4.5%, P = 0.029).CONCLUSIONS: Initial results of the prospective multicentre ESPOIR Trial showed DPH to be safe and efficient. Current DPH results including Registry data were superior to BJV and CH.Trial registration clinicaltrials.gov identifier: NCT02035540.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Boethig D, Horke A, Hazekamp M, et al. A European study on decellularized homografts for pulmonary valve replacement: initial results from the prospective ESPOIR Trial and ESPOIR Registry data†. Eur J Cardiothorac Surg. 2019. PMID: 30879050. doi:10.1093/ejcts/ezz054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。